CPHI (China Pharma Holdings) Rentabilitas dodolan miturut bathi reged

Geopolitical tensions between the US and China are limiting the global sales of China Pharma Holdings (CPHI), triggering a decline in profitability within the generics sector. The gross margin as a percentage of revenue on the GURU.Markets daily chart clearly confirms this trend, where the indicator reaches -57.00. Close cooperation with Chinese pharmacies and hospitals regarding the supply of affordable psychotropic drugs is stabilizing the situation.
Rincian analitis lan laporan data perusahaan China Pharma Holdings, Inc. (CPHI)

The fundamental stability of China Pharma Holdings (CPHI) depends on management's ability to optimize direct production costs. The implementation of ESG standards and the greening of raw material supply chains directly impact the cost of goods sold, which is reflected in profit dynamics. By analyzing the estimated gross margin, an investor can see the portion of revenue remaining after deducting material costs, thereby assessing the efficiency of resource control and the risk of overpaying for the asset.